AR034249A1 - USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS - Google Patents

USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS

Info

Publication number
AR034249A1
AR034249A1 ARP010100993A ARP010100993A AR034249A1 AR 034249 A1 AR034249 A1 AR 034249A1 AR P010100993 A ARP010100993 A AR P010100993A AR P010100993 A ARP010100993 A AR P010100993A AR 034249 A1 AR034249 A1 AR 034249A1
Authority
AR
Argentina
Prior art keywords
alkyl
mono
alkoxy
halogen
alkylamino
Prior art date
Application number
ARP010100993A
Other languages
Spanish (es)
Original Assignee
Orion Corp
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp, Juvantia Pharma Ltd Oy filed Critical Orion Corp
Publication of AR034249A1 publication Critical patent/AR034249A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

El uso de compuestos derivados de quinolina de la fórmula (1), en donde: R1 es H ó alquilo C1-6; cada R2 es independientemente OH, halógeno, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- ó di-alquilamino C1-6, alquil C1-6-S- ó hidroxialquilo C1-6; A es un anillo de benceno o cicloalquilo C5-7; cuando A es un anillo de benceno cada R3 es independientemente OH, halógeno, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- o di-alquilamino C1-6, alquil C1-6-CO-, mono- o di-alquilcarbamoilo C1-6, alquil C1-6-S-, hidroxialquilo C1-6 ó NH2-CO-; cuando A es cicloalquilo C5-7, cada R3 es independientemente OH, halógeno, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6 ó hidroxialquilo C1-6; R4 y R5 forman, junto con el átomo de nitrógeno en donde están unidos, un resto de fórmula (2), en donde X es O ó =NR6; R6 es H, OH, NH2, alquilo C1-6, alquenilo C2-6, CN-alquilo C1-6, alcoxi C1-6-CO-alquil C1-6, alquil C1-6-CO-, NH2-CO-, mono- o di-alquilcarbamoilo C1-6, hidroxialquilo C1-6, cicloalquilo C3-6, fenilo, naftilo, bencilo, en donde el fenilo, naftilo o bencilo está opcionalmente sustituido con 1 a 3 sustituyentes cada uno seleccionado independientemente de OH, halógeno, NO2, NH2, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6 y haloalquilo C1-6; o R4 y R5 forman, junto con el átomo de nitrógeno en donde están unidos, un resto de fórmula (3) en donde n es 1 ó 2; R6 es como se define anteriormente; y r es 0 a 3; o R4 y R5 forman, junto con el átomo de nitrógeno en donde están unidos, 1-imidazolilo, 1-imidazolinilo ó 1-triazolilo, cada uno de los cuales puede estar opcionalmente sustituido con 1 a 3 sustituyentes, R7, cada uno seleccionado independientemente de alquilo C1-6 y NH2; o uno de R4 y R5 es -SO2R8 y el otro de R4 y R5 es H o alquilo C1-6; R8 se selecciona independientemente a partir de alquilo C1-6, fenilo, naftilo y bencilo, en donde el fenilo, naftilo o bencilo está opcionalmente sustituido con 1 a 3 sustituyentes R9, cada uno seleccionado independientemente a partir de OH, halógeno, NO2, NH2, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6; Ra y Rb son independientemente H, OH, halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- o di-alquilamino C1-6, alquil C1-6-S- ó CN; o Ra y Rb forman, junto con los átomos del anillo de carbono en donde están unidos, un anillo de benceno condensado opcionalmente sustituido con 1 a 3 sustituyentes R'3 cada uno seleccionado independientemente a partir de OH, halógeno, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- o di-alqulamino C1-6, alquil C1-6-CO-, mono- o di-alquilcarbamoilo C1-6, y alquil C1-6-S-, hidroxialquilo C1-6 o NH2-CO-; o Ra y Rb forman, junto con los átomos del anillo de carbono en donde están unidos, un anillo carboxílico de 5 a 7 miembros, condensado opcionalmente sustituido con 1 a 4 sustituyentes R10 cada uno seleccionado independientemente a partir de OH, halógeno, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6, e hidroxialquilo C1-6; o Ra y Rb forman, junto con los átomos del anillo de carbón en donde están unidos, un anillo de biciclo[2.2.1]-heptano condensado opcionalmente sustituido con 1 a 4 sustituyentes cada uno seleccionado independientemente a partir de OH, halógeno, alquilo C1-6, y alcoxi C1-6; o Ra y Rb forman, junto con los átomos del anillo de carbono en donde están unidos, un anillo heterocíclico de 5 a 6 miembros, condensado con un heteroátomo de anillo =NR11, anillo heterocíclico que está opcionalmente sustituido con 1 a 3 sustituyentes R10 como se define anteriormente; R11 es H o alquilo C1-6, o R11 es fenilo opcionalmente sustituido con 1 a 3 sustituyentes R12 cada uno seleccionado independientemente a partir de OH, halógeno, NO2, NH2, alquilo C1-6, alcoxi C1-6 y mono- o di-alquilamino C1-6; m es 0 a 3; y t es 0 a 3; o sales y ésteres farmacéuticamente aceptables de los mismos, en la fabricación de un medicamento para el tratamiento de enfermedades o condiciones donde se indica que son efectivos los antagonistas alfa-2. Preferiblemente en el tratamiento de trastornos del sistema nervioso central. Compuestos derivados de quinolina y composiciones farmacéuticas que los comprenden.The use of quinoline-derived compounds of the formula (1), wherein: R1 is H or C1-6 alkyl; each R2 is independently OH, halogen, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 haloalkyl, NO2, NH2, mono- or di- C1-6 alkylamino, C1-6-S-alkyl C1-6 hydroxyalkyl; A is a benzene or C5-7 cycloalkyl ring; when A is a benzene ring each R3 is independently OH, halogen, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 haloalkyl, NO2, NH2, mono- or di- C1-6 alkylamino, alkyl C1-6-CO-, mono- or di-C1-6 alkylcarbamoyl, C1-6-S- alkyl, C1-6 hydroxyalkyl or NH2-CO-; when A is C5-7 cycloalkyl, each R3 is independently OH, halogen, C1-6 alkyl, C1-6 alkoxy, mono- or di- C1-6 alkylamino or C1-6 hydroxyalkyl; R4 and R5 form, together with the nitrogen atom where they are attached, a remainder of formula (2), where X is O or = NR6; R6 is H, OH, NH2, C1-6 alkyl, C2-6 alkenyl, CN-C1-6 alkyl, C1-6-alkoxy-C1-6 alkyl, C1-6-CO- alkyl, NH2-CO-, mono- or di-C 1-6 alkylcarbamoyl, C 1-6 hydroxyalkyl, C 3-6 cycloalkyl, phenyl, naphthyl, benzyl, wherein phenyl, naphthyl or benzyl is optionally substituted with 1 to 3 substituents each independently selected from OH, halogen , NO2, NH2, C1-6 alkyl, C1-6 alkoxy, mono- or di- C1-6 alkylamino and C1-6 haloalkyl; or R4 and R5 form, together with the nitrogen atom where they are attached, a residue of formula (3) where n is 1 or 2; R6 is as defined above; and r is 0 to 3; or R4 and R5 form, together with the nitrogen atom where they are attached, 1-imidazolyl, 1-imidazolinyl or 1-triazolyl, each of which may be optionally substituted with 1 to 3 substituents, R7, each independently selected C1-6 alkyl and NH2; or one of R4 and R5 is -SO2R8 and the other of R4 and R5 is H or C1-6 alkyl; R8 is independently selected from C1-6 alkyl, phenyl, naphthyl and benzyl, wherein the phenyl, naphthyl or benzyl is optionally substituted with 1 to 3 R9 substituents, each independently selected from OH, halogen, NO2, NH2 , C1-6 alkyl, C1-6 alkoxy, mono- or di- C1-6 alkylamino; Ra and Rb are independently H, OH, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, NO 2, NH 2, mono- or di- C 1-6 alkylamino, C1-6-S- or CN alkyl; or Ra and Rb together with the carbon ring atoms where they are attached, a condensed benzene ring optionally substituted with 1 to 3 R'3 substituents each independently selected from OH, halogen, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 haloalkyl, NO2, NH2, mono- or di- C1-6 alkylamino, C1-6-CO- alkyl, mono- or di-C1-6 alkylcarbamoyl, and C1-alkyl -6-S-, C1-6 hydroxyalkyl or NH2-CO-; or Ra and Rb together with the carbon ring atoms where they are attached, a 5 to 7 membered carboxylic ring, optionally substituted with 1 to 4 R10 substituents each independently selected from OH, halogen, C1 alkyl -6, C1-6 alkoxy, mono- or di- C1-6 alkylamino, and C1-6 hydroxyalkyl; or Ra and Rb together with the carbon ring atoms where they are attached, a condensed bicyclo [2.2.1] -heptane ring optionally substituted with 1 to 4 substituents each independently selected from OH, halogen, alkyl C1-6, and C1-6 alkoxy; or Ra and Rb form, together with the carbon ring atoms where they are attached, a 5- to 6-membered heterocyclic ring, fused to a ring heteroatom = NR11, heterocyclic ring that is optionally substituted with 1 to 3 R10 substituents as defined above; R11 is H or C1-6 alkyl, or R11 is phenyl optionally substituted with 1 to 3 R12 substituents each independently selected from OH, halogen, NO2, NH2, C1-6 alkyl, C1-6 alkoxy and mono- or di -C 1-6 alkylamino; m is 0 to 3; and t is 0 to 3; or pharmaceutically acceptable salts and esters thereof, in the manufacture of a medicament for the treatment of diseases or conditions where alpha-2 antagonists are indicated to be effective. Preferably in the treatment of disorders of the central nervous system. Quinoline-derived compounds and pharmaceutical compositions that comprise them.

ARP010100993A 2000-03-01 2001-03-01 USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS AR034249A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (en) 2000-03-01 2000-03-01 Quinoline and naphthalene derivatives as alpha-2 antagonists

Publications (1)

Publication Number Publication Date
AR034249A1 true AR034249A1 (en) 2004-02-18

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100993A AR034249A1 (en) 2000-03-01 2001-03-01 USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS

Country Status (21)

Country Link
EP (1) EP1263733A2 (en)
JP (1) JP2003525274A (en)
KR (1) KR20020089372A (en)
CN (1) CN1468224A (en)
AR (1) AR034249A1 (en)
AU (1) AU2001239331A1 (en)
BR (1) BR0108816A (en)
CA (1) CA2400657A1 (en)
CZ (1) CZ20022880A3 (en)
EE (1) EE200200490A (en)
FI (1) FI20000480A0 (en)
HU (1) HUP0204458A3 (en)
IL (1) IL151093A0 (en)
MX (1) MXPA02008402A (en)
NO (1) NO20024159D0 (en)
PE (1) PE20011084A1 (en)
PL (1) PL357874A1 (en)
RU (1) RU2002125944A (en)
SK (1) SK12332002A3 (en)
WO (1) WO2001064645A2 (en)
ZA (1) ZA200206956B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1628109A (en) * 2002-02-05 2005-06-15 诺沃挪第克公司 Novel aryl- and heteroarylpiperazines
ATE374773T1 (en) 2002-04-03 2007-10-15 Orion Corp POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS
WO2003082825A1 (en) * 2002-04-03 2003-10-09 Orion Corporation Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
AU2003224482A1 (en) * 2002-04-30 2003-11-17 Korea Research Institute Of Chemical Technology Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
EP1968961A2 (en) 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
RU2008150485A (en) * 2006-05-22 2010-06-27 Янссен Фармацевтика Н.В. (Be) SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
US8318927B2 (en) 2006-05-23 2012-11-27 High Point Pharmaceuticals, Llc 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
CN102295606A (en) 2006-05-29 2011-12-28 高点制药有限责任公司 Method of combining 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine,and applicable intermediates thereof its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
TWI457122B (en) 2007-07-20 2014-10-21 Orion Corp 2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
US8324213B2 (en) 2008-10-07 2012-12-04 Merck Sharp & Dohme Corp. Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
MX2012006580A (en) * 2009-12-11 2012-09-28 Genecode As Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators.
CN103524413B (en) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 hydrogenated acridine derivative and application thereof
JOP20200052A1 (en) * 2013-12-19 2017-06-16 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
WO2015153535A1 (en) 2014-03-31 2015-10-08 MiRx Pharmaceuticals, LLC Novel hdmx inhibitors and their use for cancer treatment
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (en) * 2017-07-01 2020-04-28 广东医科大学 4-flexible amino-2-arylvinyl quinoline derivative and preparation method and application thereof
JP2024536926A (en) * 2021-09-07 2024-10-08 ギズモ セラピューティクス インコーポレイテッド Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof - Patents.com

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
NO20024159L (en) 2002-08-30
ZA200206956B (en) 2003-12-01
CA2400657A1 (en) 2001-09-07
AU2001239331A1 (en) 2001-09-12
IL151093A0 (en) 2003-04-10
HUP0204458A3 (en) 2004-07-28
FI20000480A0 (en) 2000-03-01
CZ20022880A3 (en) 2003-06-18
KR20020089372A (en) 2002-11-29
CN1468224A (en) 2004-01-14
PL357874A1 (en) 2004-07-26
NO20024159D0 (en) 2002-08-30
PE20011084A1 (en) 2001-10-25
WO2001064645A3 (en) 2001-12-27
EE200200490A (en) 2003-12-15
HUP0204458A2 (en) 2003-04-28
MXPA02008402A (en) 2003-10-14
SK12332002A3 (en) 2003-07-01
RU2002125944A (en) 2004-02-27
WO2001064645A2 (en) 2001-09-07
BR0108816A (en) 2002-12-10
EP1263733A2 (en) 2002-12-11
JP2003525274A (en) 2003-08-26

Similar Documents

Publication Publication Date Title
AR034249A1 (en) USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS
HUP0301236A2 (en) Substituted quinazoline derivatives and their use as inhibitors
PE20220931A1 (en) PYRAZOLO[3,4-B]PYRAZINE-TYPE SHP2 PHOSPHATASE INHIBITORS
AR037489A1 (en) REPLACED KINOLINS AND PROCESS FOR PREPARATION
AR061815A1 (en) OXO-PROLINAMIDE COMPOSITE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR049711A1 (en) HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE
AR053092A1 (en) COMPOUNDS DERIVED FROM PHENOXYACETIC ACID AND INTERMEDIATE SYNTHESIS COMPOUNDS
AR052943A1 (en) DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE
AR060658A1 (en) DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
AR055878A1 (en) CYCLOPROPANOCARBOXAMIDE DERIVATIVES
AR062074A1 (en) ALKYLENE 1-PHENYL-2-PYRIDINYL ALCOHOL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
PE20080841A1 (en) QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO STRESS OR DEPRESSION
AR069510A1 (en) ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10
AR032361A1 (en) DERIVATIVES OF ANDROSTAN AND SALTS AND SOLVATOS OF THE SAME, ITS USE FOR THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS
AR030596A1 (en) DERIVATIVES OF QUINOLINA AND QUINAZOLINA, A PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, USE OF THE SAME FOR THE DEVELOPMENT OF MEDICINES
AR049696A1 (en) INDOL DERIVATIVES
AR082152A1 (en) DERIVATIVES OF N- (METILSULFONIL) BENZAMIDE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF NAV1.7
AR060605A1 (en) DERIVATIVES OF DIAZEPAN AS ANTAGONISTS OF THE CCR2 RECEIVER
ECSP11011083A (en) NEW COMPOUNDS
AR065531A1 (en) PIRIMIDINE DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS.
CY1116183T1 (en) Piperazinoidions as antagonists of oxytocin receptors
AR049346A1 (en) 3-AMINO-1-ARILPROPIL-INDOLES AS MONOAMINE REABSORTION INHIBITORS
AR065811A1 (en) DERIVATIVES OF 2-AMINO-4H-IMIDAZOL-4-ONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS.
AR060811A1 (en) MGLUR5 V MODULATORS
AR040626A1 (en) USEFUL QUINOLINE DERIVATIVES AS NEUROPEPTIDE RECEIVER AND (NPY)

Legal Events

Date Code Title Description
FB Suspension of granting procedure